Long way to go for AYUSH
The proposal to set up a separate arm of the CDSCO to scrutinise applications meeting AYUSH specifications has received mixed…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Management
Pernicious osteoporosis
Osteoporosis is a condition that results in loss of bone strength and density, causing bones to become more fragile and easily…
CDSCO draft guidelines: Industry gives its verdict
Recently, the Central Drugs Standard Control Organisation (CDSCO) called for recommendations and suggestions on its draft…
Achieving high performance in pharma through supply chain analytics
Soumendra Mohanty, Global Lead, Information Management Services, Accenture, gives an indepth idea about how stronger analytical…
Granules India on the Growth Path
Granules India is one of the world's leading manufacturers of Active Pharmaceuticals Ingredients (APIs), Pharmaceutical…
Tasting new trends in health supplements market
CubeX’s comprehensive report titled ‘Tasting New Trends in the Indian Health Supplements Market’, gives a detailed understanding…
Exim Bank releases study on Indian chemical industry
Study titled ‘Indian Chemical Industry: Exploring Global Demand’, shows that Indian chemical industry has a lot of export…
FDI tangle: And the vote goes to….?
Usha Sharma outlines the various aspects of the foreign direct investment (FDI) debate which has gripped the entire pharma sector…
Epilepsy: More awareness needed
Many in India suffer from epilepsy and there are many who require treatments to overcome this disease. Express Pharma, in…
A new sobriquet for SMS service-Substituted Medicine Service
B Sriram, Executive Director–Healthcare, Direxions Marketing Solutions expounds his views on SMS service being utilised to give…
To be or not to be…
Maharashtra Food and Drug Administrations's (FDA) decision to forbid Ayurveda, Yoga and Naturopathy, Unani, Siddha, Homeopathy…
Global biotechs financial performance stabilising: EY report
The global biotechnology industry has witnessed a second straight year of increasingly stable financial performance in 2011,…
FSSA and the emerging OTC landscape
Anil Khanna, an independent strategic consultant and investment banker, talks about FSSA guidelines and its implications OTC drugs…
Regulatory woes of pharma SMEs
Jagmohan Rai Agarwal, after elucidating about the regulatory woes of the Indian pharmaceutical industry in the last issue, draws…
ACTA Down, but What Next?
The EU Parliament has rejected the Anti-Counterfeiting Trade Agreement (ACTA), but there are other similar moves to restrict free…
Drug pricing norms: Cost or MRP based?
As the second largest exporter of bulk drugs and largest formulation exporter, the Indian pharmaceutical industry has made its…
Venus Remedies: Reinventing R&D
Generic dominated Indian pharma market also has exceptions like Venus Remedies who wants to make transition from generic to…
Regulatory woes of pharma SMEs (Part I)
Jagmohan Rai Agarwal has experienced the workings of the Indian drug regulatory authorities across the country while engaged in…
Back to the roots Landscaping OTC opportunities in the Indian ayurveda market
Sreedevi Yallamrazu, Senior Strategic Analyst, CubeX comments on the acceptance of traditional medicine for holistic health and…
A holistic view of the HPAPI opportunity
The High Potency Active Pharmaceutical Ingredients (HPAPI) segment is the potential cash cow of the pharma procurement basket but…